We are live on ! Find out more
GYRE icon

Gyre Therapeutics

41 hedge funds and large institutions have $21.6M invested in Gyre Therapeutics in 2024 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 16 increasing their positions, 11 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

6,538% more call options, than puts

Call options by funds: $1.06M | Put options by funds: $16K

158% more capital inflows, than outflows

Capital inflows: $1.4M | Capital outflows: $542K

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

45% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 11

11% more funds holding

Funds holding: 37 → 41 (+4)

0.21% more ownership

Funds ownership: 1.88% → 2.08% (+0.21%)

Holders
41
Holders Change
+4
Holders Change %
+10.81%
% of All Funds
0.54%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
16
Reduced
11
Closed
2
Calls
$1.06​M
Puts
$16​K
Net Calls
+$1.05​M
Net Calls Change
-⁠$39​K

GYRE Hedge Fund Activity: Q4 2024 in Review

41 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q4 2024, worth a combined $21.6M — up 7.1% from $20.2M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new GYRE positions and 2 closed out — a net gain of 3 holders — while 16 added to existing stakes and 11 trimmed.

The largest buyer was UBS Group, adding an estimated $684K. The largest seller was Advantage Alpha Capital Partners, cutting an estimated $227K.

  • 41 institutional investors held Gyre Therapeutics (GYRE) as of Q4 2024, up from 37 in Q3 2024.
  • Funds reported $21.6M of Gyre Therapeutics stock for Q4 2024, up 7.1% quarter-over-quarter.
  • 5 funds opened new Gyre Therapeutics positions in Q4 2024 and 2 closed out, a net change of +3 holders.
  • The largest Gyre Therapeutics buyer in Q4 2024 was UBS Group, an estimated $684K added.
  • The largest Gyre Therapeutics seller in Q4 2024 was Advantage Alpha Capital Partners, an estimated $227K sold.

Based on aggregated 13F filings for Q4 2024.